1. Introduction {#section0005}
===============

Community acquired respiratory tract infections are frequent and constitute an important cause of morbidity in Sweden and other European countries. A significant part of these infections are caused by viral pathogens ([@bib2], [@bib3]). It is often difficult for the clinician to distinguish between viral and bacterial aetiologies, and this may result in overuse of antibiotics ([@bib10]). Diagnosis of viral respiratory tract infections using viral culture, antigen detection or serology is either too slow or too insensitive to be applicable in clinical practice ([@bib5]). The more reliable, specific and sensitive PCR methods have not yet won acceptance as the first choice for diagnosis owing to the high cost when several agents are targeted. Recently, multiplex assays that detect a large number of viral agents have been described. Some of these are based on traditional PCR ([@bib1], [@bib4], [@bib9], [@bib11]), others on real-time PCR ([@bib5], [@bib7], [@bib12], [@bib14]) or PCR combined with Luminex liquid chip hybridization and identification ([@bib8]).

2. Methods {#section0010}
==========

We developed a real-time PCR procedure, based on automated specimen extraction and multiplex amplification, at a relatively low cost (€33). Primers and hydrolysis probes were obtained from the literature or developed in our laboratory. The following agents were analysed: influenza virus A (IfA) and B (IfB), parainfluenza 1-3 (PIV), human metapneumovirus (MPV), respiratory syncytial virus (RSV), rhinovirus (RV), enterovirus (EV), adenovirus (AdV), human coronaviruses 229E, OC43 and NL63. In addition, M. pneumoniae and Ch. pneumoniae were included in the panel.

Nucleic acid from 100 μL of specimen was extracted into an elution volume of 100 μL by a Magnapure LC robot (Roche Molecular Systems, Mannheim, Germany), using the Total Nucleic Acid protocol, and was amplified in an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA). Amplification was then carried out in 50 μL reaction volumes, including 10 μL of sample preparation and 25 μL of one-step RT-PCR master mix from Applied Biosystems (this was exchanged to a master mix from Invitrogen (Carlsbad, CA) in the later part of the study period to improve sensitivity). After a reverse transcription step at 46 °C for 30 min followed by 10 min of denaturation at 95 °C, 45 cycles of two-step PCR was performed (15 s at 95 °C, 60 s at 58 °C). Each sample was amplified in 5 parallel reactions, each containing primers and probes specific for 3 targets (mixtures A--E), as described in [Table 1](#tbl1){ref-type="table"} . Multiplexing tended to hamper the performance of the amplification significantly for many combinations, and therefore the reagent mixtures were carefully evaluated: combinations were only accepted if the Ct value in multiplex was no more than 2 cycles higher than when detection was carried out in separate reactions. The performance was evaluated using pUC57 plasmids with inserts of the targeted viral or bacterial sequences, synthesized by by GenScript Corp. (Piscataway, NJ).Table 1Primers and probes used in multiplex real-time PCR run in five reaction mixtures, A-EMixPrimer/ProbeSequenceOriginReporterAPIV-1_FGTTGTCAATGTCTTAATTCGTATCAATAATT[@bib14]APIV-1_RGTAGCCTMCCTTCGGCACCTAA[@bib14]API V-l\_ ProbeTAGGCCAAAGATTGTTGTCGAGACTATTCCAA[@bib14]FAM-TAMRAAPIV-2_FGCATTTCCAATCTTCAGGACTATGA[@bib14]APIV-2_RACCTCCTGGTATAGCAGTGACTGAAC[@bib14]APIV-2_ProbeCCATTTACCTAAGTGATGGAATCAATCGCAAA[@bib14]FAM-TAMRAAPIV-3_FTo be published elsewhere[a](#tbl1fn1){ref-type="table-fn"}APIV-3_RTo be published elsewhere[a](#tbl1fn1){ref-type="table-fn"}APIV-3_ProbeTo be published elsewhere[a](#tbl1fn1){ref-type="table-fn"}FAM-BHQBIfB_FAAATACGGTGGATTAAATAAAAGCAA[a](#tbl1fn1){ref-type="table-fn"}BIfB_RCCAGCAATAGCTCCGAAGAAA[a](#tbl1fn1){ref-type="table-fn"}BIfB_ProbeCACCCATATTGGGCAATTTCCTATGGC[a](#tbl1fn1){ref-type="table-fn"}JOE-TAMRABRSV_FGCAAATATGGAAACATACGTGAACAThis publBRSV_RGCACCCATATTGTWAGTGATGCAThis publBRSV_ProbeCTTCACGAAGGCTCCACATACACAGCWGThis publFAM-BHQBNL63_FACGTACTTCTATTATGAAGCATGATATTAA[@bib5]BNL63_RAGCAGATCTAATGTTATACTTAAAACTACG[@bib5]BNL63_PATTGCCAAGGCTCCTAAACGTACAGGTGTT[@bib5]HEX-BHQ1CMPV_FATGTCTCTTCAAGGGATTCACCTThis publCMPV_RAMAGYGTTATTTCTTGTTGCAATGATGAThis publCMPV_ProbeCATGCTATATTAAAAGAGTCTCARTACThis publFAM-MGBCCh. pneumoniae_FCAAGGGCTATAAAGGCGTTGCTThis publCCh. pneumoniae_RATGGTCGCAGACTTTGTTCCAThis publCCh. pneumoniae_PTCCCCTTGCCAACAGACGCTGGThis publCY5-BHQCEV_FCATGGTGYGAAGAGTCTATTGAGCTAThis publCEV_RGGACACCCAAAGTAGTCGGTTCThis publCEV_probeCGGCCCCTGAATGCGGCTAATCThis publHEX-BHQ1DIfA_FAAGACCAATCCTGTCACCTCTGA[@bib13]DIfA_RCAAAGCGTCTACGCTGCAGTCC[@bib13]DIfA_ProbeTTTGTGTTCACGCTCACCGT[@bib13]FAM-MGBDAdV_FGCCACGGTGGGGTTTCTAAACTT[@bib6]DAdV_RGCCCCAGTGGTCTTACATGCACATC[@bib6]DAdV_ProbeTGCACCAGACCCGGGCTCAGGTACTCCGA[@bib6]HEX-BHQ1DOC43_FCGATGAGGCTATTCCGACTAGGT[@bib5]DOC43_RCCTTCCTGAGCCTTCAATATAGTAACC[@bib5]DOC43_ProbeTCCGCCTGGCACGGTACTCCCT[@bib5]CY5-BHQ2ERV_F1GGTGTGAAGAGCCSCRTGTGCTThis publicationERV_F2GGTGTGAAGACTCGCATGTGCTThis publicationERV_F3GGGTGYGAAGAGYCTANTGTGCTThis publicationERV_R3GGACACCCAAAGTAGTYGGTYCThis publicationERV_probeCCGGCCCTGAATGYGGCTAAYCThis publicationFAM-BHQ1EMycoplasma_FGGAATCCCAATGCACAAGAACAThis publicationEMycoplasma_RGCTTTGGTCAACACATCAACCTTThis publicationEMycoplasma_ProbeGCCTTGAAGGCTGGGTTTGCGCTAThis publicationCY5-BHQE229E_FCAGTCAAATGGGCTGATGCA[@bib5]E229E_RAAAGGGCTATAAAGAGAATAAGGTATTCT[@bib5]E229E_PCCCTGACGACCACGTTGTGGTTCA[@bib5]HEX-BHQ1[^1]

3. Results {#section0015}
==========

During the period from October 2006 through March 2007, 954 specimens were collected from patients of all ages with symptoms of respiratory tract infections who had been admitted to hospital clinics as well as health care centers in the Göteborg region in Western Sweden (catchments area of approximately 600,000 inhabitants). Both in-patients and out-patients were included. The specimens were obtained from either oropharynx or nasopharynx by rotating swabs. The specimens were submitted for diagnosis to the virology laboratory at Sahlgrenska University Hospital.

Out of the 954 specimens analysed 457 (48%) were positive for one ore more agents. The following agents were detected in order of frequency (*n*, % of positives): IfA (*n*  = 114, 25%), RV (*n*  = 93, 20%), MPV (*n*  = 46, 10%), RSV (*n*  = 41, 9%), OC43 (*n*  = 33, 7%), Ad (*n*  = 33, 7%), NL63 (*n*  = 26, 6%), PIV (*n*  = 19, 4%), IfB (*n*  = 4, 1%), and EV (*n*  = 1). M. pneumoniae was the most frequent bacterium (*n*  = 44, 10%) whereas Ch. pneumoniae was found only in 2 specimens. Thirty-one specimens were positive for two agents, and one specimen was positive for 3 agents. The procedure was run every working day and results from samples arriving in the morning could be delivered during the same day to the clinician. The positivity rate (48%) is comparable with previous reports with similar study subjects. The rate of RSV and IfB were remarkably low, probably because these infections had appeared in extensive epidemics the preceding year.

By targeting multiple agents in each reaction well, a broad range of aetiologies could be investigated in each run. The cost per sample could be kept low, since the procedure was streamlined and a reasonable number of samples arrived to the laboratory each day. The cost for was divided on reagents for nucleic acid extraction (€3), reagents for real-time PCR (€11), personnel (€8), laboratory space (€3), instrument cost (€1), and overhead (€5), yielding a customer price of €33.

4. Discussion {#section0020}
=============

We believe that a combination of low cost, high accuracy and prompt result delivery is the key to achieving a wide clinical use of molecular diagnostics of respiratory infections. We have also noted that inclusion of bacterial agents has promoted the willingness from clinicians to use our service, probably because Mycoplasma pneumoniae or Ch. pneumoniae infections may require antibiotic treatment. Viral detection may support the clinician\'s decision to avoid antibiotics, or may prompt antiviral treatment such as oseltamivir (against influenza) to the patient or exposed family members. Identifying the aetiology also allows the clinician to better inform the patient about the prognosis and ways of limiting the spread to other individuals. We therefore believe that an expanded use of molecular diagnostics of respiratory infections is of great clinical value. It should, of course, be kept in mind that viral agents detected by highly sensitive assays might reflect asymptomatic infection rather that being the cause of the present illness, and that an identified viral agent does not exclude concomitant bacterial infection. To some extent, the probability that a given agent constitutes an aetiological agent should be related to the Ct value: The lower Ct value, the higher the probability, and this may also be of relevance for the interpretation of double infections. Further studies of respiratory infection aetiologies in different patient categories, and of the clinical utility of this and similar multiplex assays, need to be carried out.

We are grateful to Dr Lars Nielsen, Copenhagen, for sharing experience, oligonucleotide sequences and samples.

[^1]: Personal communication from Dr Lars Nielsen, Copenhagen. FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; JOE, dichloro-2′,7′-dimethoxy-6-carboxyfluorescein; HEX, hexachlorofluorescein; CY5, Cyanine-5; BHQ, black-hole quencher; MGB, minor groove binder.
